-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

Benzinga·08/07/2026 17:10:09
Listen to the news
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $23.